APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 403 participants.

Also called NCT02789917

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 403 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02789917
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02789917. Randomized; no masking; primary purpose treatment. Start 2016-06 (registry gives no type); primary completion 2020-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF
Acronym
APPROACH
Condition
Acute Coronary Syndrome
Intervention (Other)
Dual Therapy
Intervention (Other)
Triple Therapy
Lead sponsor
LMU Klinikum (class: other)
Collaborator
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (class: other)
Collaborator
Technical University of Munich (class: other)
Collaborator
Helmholtz Zentrum München (class: industry)
Collaborator
University of Göttingen (class: other)
Collaborator
University of München (class: other)
Collaborator
University Medicine Greifswald (class: other)

Record details

Record id
cardio:ct-nct02789917
Content hash
0983c14e858e9a0161ce88407b18d04f1ceb0903bb35c9f355d6e54291cf2a66